Click here to read the newsletter.
A little more than three months have passed since our shares were listed on Nasdaq First North and, at Xintela, we are progressing with our development programs and our goals according to plan.
In April, we communicated that we had initiated a study on cartilage damage in horses in the US, with a planned read out at the end of the year. Our preclinical stem cell development in Germany is also progressing well. In parallel with these studies, we are evaluating the effect of our antibodies on the growth and survival of glioblastoma cells in both in vitro and animal models. Since our listing, we have strengthened our organisation with the recruitment of Caroline Ehrencrona as Director Clinical Development and Regulatory Affairs and Christer Betsholtz as scientific and strategic advisor in our cancer project. In addition, we are working to increase our international presence and have attended conferences in both Japan (cell therapy in cartilage damage) and Poland (brain tumours).
In this newsletter, Caroline Ehrencrona answers questions about her initial impressions of Xintela. We also cover our visit to Poland, an interesting scientific article on cancer research published by an American research group and about the communication of our patent portfolio.
I will take this opportunity to wish all our shareholders a wonderful summer and share my hopes of an exciting remainder of the year.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.
Investor presentation from Lund - Jan 27
Interview with Xintelas CEO